Dr Kay T Vien, OD in Belle Isle, FL - Optometrist

Dr Kay T Vien, OD is a Optometrist based in Belle Isle, Florida. Dr Kay T Vien is licensed to practice in Florida (license number OPC4260) and her current practice location is 4413 Hoffner Ave, Belle Isle, Florida. She can be reached at her office (for appointments etc.) via phone at (407) 207-5310.

NPI number for Dr Kay T Vien is 1083898928 and her current mailing address is 4413 Hoffner Ave, Belle Isle, Florida. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1083898928.

Contact Information

	Dr Kay T Vien, OD
	4413 Hoffner Ave, Belle Isle, FL 32812-2331
	(407) 207-5310
	Not Available

Healthcare Provider's Profile

Full Name	Dr Kay T Vien
Gender	Female
Speciality	Optometrist
Location	4413 Hoffner Ave, Belle Isle, Florida
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1083898928
Provider Enumeration Date: 12/27/2007
Last Update Date: 03/21/2016

Medical Identifiers

Medical identifiers for Dr Kay T Vien such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1083898928	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	OPC4260 (Florida)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Kay T Vien is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Kay T Vien, OD 4413 Hoffner Ave, Belle Isle, FL 32812-2331 Ph: (407) 207-5310	Dr Kay T Vien, OD 4413 Hoffner Ave, Belle Isle, FL 32812-2331 Ph: (407) 207-5310

News Archive

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

Accelerated accumulation of abdominal fat during menopause linked to heart disease risk

Women who experience an accelerated accumulation of abdominal fat during menopause are at greater risk of heart disease, even if their weight stays steady, according to a University of Pittsburgh Graduate School of Public Health-led analysis published today in the journal Menopause.

Research roundup: Effectiveness of mobile clinics; Can more alternative medicine coverage save money?

Approximately 2,000 mobile health clinics in the U.S. have 6.5 million patient visits annually. Researchers analyzed data from nearly 6,000 patients from 2010 to 2012 from one program, to examine the clinical impact and cost-effectiveness.

Mylan, Pfizer partner to develop and market generic drugs in Japan

Pfizer Inc. and Mylan Inc. today announced that they have signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. The collaboration is designed to build upon each company's highly complementary strengths and quality assets.

Dr Kay T Vien, OD - Optometrist in Belle Isle, FL